ACC offers (1→3)-ß-D-glucan analysis to support the diagnosis of Invasive Fungal Disease (IFD) in at risk patients. Testing services are provided through our reference laboratory, Beacon Diagnostics®, a CLIA-certified laboratory specializing in (1→3)-ß-D-glucan analysis. Please visit the Beacon Diagnostics® Laboratory website for reference information, certificates/licenses and instructions on submitting samples.
In addition to our clinical diagnostics laboratory services we also offer the Fungitell® Kit which is an in-house diagnostic test for the detection of (1→3)-ß-D-glucan that clients can perform at their facility.
Patients at High Risk for IFD
Multiple studies have shown glucan to become elevated well in advance of conventional clinical signs and symptoms. The early diagnosis of fungal infection is associated with improved clinical outcome and is a value to clinicians. In contrast, delayed diagnosis and therapy of invasive fungal disease is associated with increased mortality. Hence, there is significant utility in the application of the Fungitell® test in at risk patients.
Immunosuppressed patients are at high risk for developing invasive fungal disease, which is often difficult to diagnose. Affected patient populations include:
- Cancer patients undergoing chemotherapy
- Stem Cell and Organ Transplant patients
- Burn patients
- HIV patients
- ICU patients